GT20029 China Phase II Trial For AGA Reached Primary Endpoint
    4/21/2024

    New to GT20029? There is a guide in the encyclopedia. Read the guide →
    At a glance
    In this treatment experience post, the primary subjects mentioned are
    💧 GT20029 (topical) 1% 2x weekly 12 weeks
    the tone is 😀 positive with statistically significant therapeutic efficacy results.

    Other terms

    The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
    View this post in the Community →
    No results